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Abstract 
Background: Patients with chronic focal epilepsy may have atrophy of brain structures 
important for the generation and maintenance of seizures. However, little research has 
been conducted in patients with newly diagnosed focal epilepsy (NDfE), despite it being a 
crucial point in time for understanding the underlying biology of the disorder. We aimed to 
determine whether patients with NDfE show evidence of volumetric abnormalities of 
subcortical structures.  
Methods: Eighty-two patients with NDfE and 40 healthy controls underwent MRI 
scanning using a standard clinical protocol. Volume estimation of the left and right 
hippocampus, thalamus, caudate nucleus, putamen and cerebral hemisphere was 
performed for all participants and normalised to whole brain volume. Volumes lower than 
two standard deviations below the control mean were considered abnormal. Volumes 
were analysed with respect to patient clinical characteristics, including treatment outcome 
12 months after diagnosis. 
Results: Volume of the left hippocampus (P(FDR‐corr) = 0.04) and left (P(FDR‐corr) = 0.002) 
and right (P(FDR‐corr) = 0.04) thalamus were significantly smaller in patients relative to 
controls. Relative to the normal volume limits in controls, 11% individual patients had left 
hippocampal atrophy, 17% had left thalamic atrophy and 9% had right thalamic atrophy. 
We did not find evidence of a relationship between volumes and future seizure control or 
with other clinical characteristics of epilepsy. 
Conclusions: Volumetric abnormalities of structures known to be important for the 
generation and maintenance of focal seizures are established at the time of epilepsy 
diagnosis and are not necessarily a result of the chronicity of the disorder. 
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Introduction
There is a wealth of evidence indicating that people with refractory focal epilepsy have 
quantitative structural brain abnormalities on magnetic resonance imaging (MRI). Atrophy 
of temporal lobe structures is frequently identified in patients with temporal lobe epilepsy 
(TLE), including the hippocampus, entorhinal cortex, perirhinal cortex and amygdala, 
preferentially ipsilateral to the side of seizure onset [1]. Extrahippocampal subcortical 
atrophy is also commonly reported, including the thalamus and striatum in both cerebral 
hemispheres [1, 2]. However, it remains unclear whether subcortical atrophy in focal 
epilepsy is pre-existing, present at the time of diagnosis as a consequence of 
epileptogenic processes, or the result of the chronicity of longstanding epilepsy and 
antiepileptic drug (AED) treatment. It is therefore important to determine whether brain 
abnormalities are already established in the early stages of epilepsy.
Despite that epileptogenesis begins prior to the onset of a first seizure [3], the earliest 
reliable time point of investigation of human epilepsy in prospective studies is at the point 
of diagnosis. Neuroimaging studies of patients with newly diagnosed epilepsy (NDE) 
have the potential to provide important information about the nature of brain 
abnormalities by separating pre-existing or novel abnormalities and longstanding 
changes originating from recurrent seizures and chronic use of AEDs [4]. The 
identification of quantitative imaging abnormalities at diagnosis may provide new insights 
into biomarkers of pharmacoresistance and cognitive comorbidities [5, 6]. Approximately 
60% of patients with NDE will achieve seizure control, ~25% will develop 
pharmacoresistant epilepsy and the remainder will fluctuate between remission and 
relapse [7]. To date, markers of pharmacoresistance in patients with NDE have been 
limited to reports in epidemiological studies and clinical trials, and suggest, for example, 
that gender, treatment history, age, and time between first seizure and diagnosis may be 
related to pharmacoresistance [8, 9]. Determining the relationship between quantitative 
brain imaging at diagnosis and AED treatment outcome is an important research 
endeavour [5]. Additionally, over 50% of patients with NDE have been found to show 
impairment in at least one cognitive domain [10]. Quantitative imaging studies may 
further contribute to the understanding of cognitive problems which may be present at 
point of diagnosis.  A
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There are few quantitative neuroimaging studies in patients with newly diagnosed focal 
epilepsy (NDfE). Although a small number of studies have identified localised brain 
atrophy in patients with NDfE, findings are inconsistent. One study revealed hippocampal 
atrophy in patients with NDfE relative to controls [11], whilst others have found no 
difference in hippocampal volume between these groups [12, 13]. Inconsistent findings 
have been reported with respect to structural changes of the cerebellum in patients with 
NDfE [13, 14]. To our knowledge, no studies have identified thalamic atrophy in adult 
NDfE, although a recent study reported thalamic atrophy in drug naïve patients with new-
onset genetic generalised epilepsy (GGE) [15].
There were two primary objectives of the present study. Firstly, we sought to determine 
whether atrophy of the hippocampus, thalamus, caudate nucleus, putamen and cerebral 
hemisphere is present at the time of diagnosis of focal epilepsy with unknown cause 
relative to healthy controls. Secondly, we aimed to explore whether volumetric changes 
of these structures are related to various clinical characteristics of the disorder including 
treatment outcome at 6 and 12 months after diagnosis.
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Methods 
Participants 
We identified patients with archived MRI, acquired according to a clinical epilepsy 
protocol, within 12 months of diagnosis of focal epilepsy of unknown cause and scanned 
on a 3 T GE Discovery MRI system at the Walton Centre NHS Foundation Trust, 
Liverpool, UK since 2015. At initial screening, 140 patients with likely NDfE and 
corresponding MRI for analysis were retrieved. More detailed assessment of patient 
clinical histories and MRI resulted in the exclusion of 58 patients due to one of the 
following factors: (1) first seizure with no diagnosis of epilepsy, (2) probable idiopathic 
generalised epilepsy, (3) symptomatic seizures or probable historical causes (e.g. 
tumour, infection, head injury), (4) presence of epileptogenic lesion (e.g. focal cortical 
dysplasia, hippocampal sclerosis), or (5) unusable or unavailable MRI data for analysis. 
This resulted in 82 patients with NDfE of unknown cause (formerly cryptogenic focal 
epilepsy) with corresponding MRI data for image analysis. All patients were diagnosed by 
consultant neurologists at the Walton Centre NHS Foundation Trust. All images were 
reported non-lesional by a neuroradiologist with expertise in the assessment of MRI for 
epileptogenic lesions. All patients had no history of learning disability. 
Additional clinical data were obtained by searching through hospital electronic records. 
We obtained age at diagnosis and seizure type (focal aware seizures [FAS], focal 
impaired awareness seizures [FIAS] and focal to bilateral tonic-clonic seizures [FBTCS]) 
for patients. Fifty-one (62.2%) had undergone EEG and we recorded whether inter-ictal 
abnormalities were captured. Seizure status at 6 and 12 months after diagnosis, hereon 
referred to as seizure outcome, was obtained for 58 patients at 6 months and 48 patients 
at 12 months. For comparison with patients, we used imaging data from a cohort of 40 
healthy adult controls that were scanned as part of a different study [16] but who had the 
equivalent MRI scans for comparative analysis. The North West – Liverpool research 
ethics committee approved this study (14/NW/0332).
MRI acquisitionA
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The standard 3 Tesla MRI protocol for patients with a new presentation of seizures at our 
centre included a high in-plane resolution T1-weighted fluid attenuated inversion recovery 
(FLAIR) MRI acquisition of the whole brain (TE 1.5 ms, TR 2500 ms, flip angle 111°, 
voxel size 0.4 mm x 0.4 mm, slice thickness 3.0 mm, FOV 220 mm, matrix size 320 x 
384). This sequence was used for analysis in the present study. Other sequences 
acquired for diagnostic purposes but not used for analysis included axial T2-weighted 
and coronal T2-FLAIR scans. 
MRI analysis
Given the slice thickness of the T1-weighted FLAIR images, we were unable to reliably 
apply automated image analysis tools to extract subcortical and hemispheric volume. We 
therefore used rigorous manual techniques to estimate the volume of subcortical and 
hemispheric structures. The volume of the left and right hippocampus, thalamus, caudate 
nucleus, putamen, and cerebral hemispheres were quantified for all participants using the 
Cavalieri method of design-based stereology [17]. This approach has been frequently 
applied to MRI data in epilepsy studies [12, 18-20], has been considered the benchmark 
measurement approach to which automated MRI techniques have been compared [19], 
and provides a mathematically unbiased and validated approach to estimate brain 
compartment volume [17, 21]. 
Using Easymeasure software [19], each volume of interest (VOI) was estimated using a 
series of parallel two-dimensional (2D) MR sections set at a constant distance apart. A 
randomly orientated grid of pixels was overlaid on each section and points intersecting 
each region-of-interest (ROI) were counted separately for the left and right structures of 
each patient and control. The pixel size used for point-counting was altered depending on 
the size of the ROI (pixel sizes: hippocampus, 4; thalamus, 6; caudate nucleus, 5; 
putamen, 6; and cerebral hemisphere, 30) in order to optimise the sampling density [17]. 
The number of points transecting the ROI was multiplied by distance between each 
consecutive section to produce volume estimates. Given that nuclei (e.g. thalamic nuclei) 
and subregions (e.g. hippocampal cornu ammonis) of structures measured are almost 
indistinguishable on clinical MRI, we measured the structures as an entire complex.A
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Stereological point counting on MR images for volume estimation of the hippocampus, 
thalamus, caudate nucleus and putamen is shown in Figure 1. Detailed information on 
the hippocampal VOI is provided elsewhere [20]. Moving along its longitudinal axis, the 
hippocampus is bound superiorly by the white, myelinated fibres of the alveus and often 
by an additional region of cerebrospinal fluid superior to the alveus. The hippocampus 
was differentiated anteriorly from the amygdala through visualisation of the alveus. The 
posterior boundary of the hippocampus was reached when the lateral ventricles divide 
into the frontal and temporal horns. The hippocampal VOI comprised the hippocampus 
proper, dentate gyrus, alveus, subiculum, presubiculum and parasubiculum; the 
amygdala, uncus, choroid plexus and grey matter above the alveus were not included in 
the measurements.
The anterior border of the thalamus began immediately posterior to the anterior 
commissure and maintained a close relationship with the internal capsule laterally and 
the central canal of the ventricles medially; the posterior border of the thalamus was the 
pulvinar. Measurements ended with the formation of the atrium of the ventricles. The 
zona incerta formed the inferior border of the thalamus. We excluded the subthalamic 
nuclei, substantia nigra, and red nuclei from thalamic measurements. The lateral and 
medial geniculate bodies and the habenular nucleus were also excluded [19]. The 
posterior border of the caudate nucleus was considered the last slide in which the 
caudate tail was still superior to the lateral ventricle. Caudate nucleus and putamen 
measurements ended with the formation of the atrium from the temporal and frontal horns 
of the lateral ventricle. Neither caudate nucleus nor putamen measurements included the 
striatal cell bridges connecting the two nuclei or the nucleus accumbens. The medial and 
lateral borders of the putamen were the internal capsule and external capsule, 
respectively [18]. The posterior border of the putamen often coincides with the 
appearance of the medial and lateral geniculate bodies. Measurement of the entire 
cerebral hemispheres was also obtained which included all supratentorial grey and white 
matter, excluding the brainstem and cerebellum. All subcortical and hemispheric volumes 
were normalised using whole brain volumes (summation of left and right cerebral 
hemispheric volumes); the proportion of each subcortical and hemispheric volume 
relative to whole brain volume was calculated. A
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Statistical analysis
The data did not meet the assumptions of parametric tests; therefore, nonparametric 
tests were used to analyse the data.  For patient-control analysis, all volumes were 
analysed using nonparametric Mann-Whitney U-tests in SPSS (version 25, 
www.spss.com). Given the significant sex difference between patients and controls, and 
the higher average age of patients compared to controls, we performed all statistical 
analyses on normalised volumes, with their residuals corrected for age and sex in a 
confound only regression model. Volumes lower than two standard deviations of the 
control mean were considered abnormal and suggestive of structural atrophy in individual 
patients. Spearman's correlations were used to investigate relationships between 
volumes and age at first seizure, years between first seizure and diagnosis, and age at 
diagnosis. Categorical analysis of clinical and neuroimaging data was performed using 
Chi-squared tests. Multiple comparisons were corrected using the false discovery rate 
(FDR) and results were considered statistically significant at P < 0.05.
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
Results
Clinical data
Table 1 presents a summary of the demographic information for patients and controls, 
and clinical data for patients. There was no significant difference between the age of 
patients (when diagnosed) and healthy controls (at time of MRI) (t = 2.8, P = 0.13). 
However, there was a significant sex difference between patients and controls, a 
reflection of more males in the patient group and more females in the control group (X2 = 
4.72, P = 0.03). More patients had FIAS compared to FAS (57.3% vs 42.7%) and most 
patients experienced FBTCS (88.9%). The majority (76.5%) of patients had a normal 
inter-ictal EEG. Two patients did not commence AED treatment. These patients did not 
have outcome data. For the remainder of the patient cohort, the first AED used was 
Lamotrigine (n = 47, 59%), Levetiracetam (n = 14, 18%), Zonisamide (n = 8, 10%), 
Carbamazepine (n = 6, 8%), Sodium Valproate (n = 3, 4%), Oxcarbazepine (n = 1, 1%) 
and Phenytoin (n = 1, 1%). We were able to obtain seizure status at 6 and 12 months 
post-diagnosis for 58 (40% seizure free) and 48 (50% seizure free) patients, respectively. 
There were no significant differences in demographic data, incidence of FAS, FIAS or 
FBTCS, or normal / abnormal EEG between patients who were seizure free and those 
who continued to experience seizures at 6 or 12 months. 
MRI volumetric changes in NDfE
Volumetric descriptive statistics are provided in Table 2. Volume of the left hippocampus 
(U = 1232, P(FDR‐corr) = 0.04), and left (U = 1002, P(FDR‐corr) = 0.002) and right (U = 1228, 
P(FDR‐corr) = 0.04) thalamus were significantly smaller in patients compared to controls 
(Figure 2). There was a trend for the right hippocampus to be smaller in patients relative 
to controls (U = 1311, P(FDR‐corr) = 0.09). There were no significant differences (P(FDR‐corr) < 
0.05) or trends for differences in volume of the left or right caudate nucleus, putamen or 
whole cerebral hemisphere between patients and controls. In patients, average volume of 
the left hippocampus was decreased by 6.9%, right hippocampus by 6.5%, left thalamus 
by 6.4%, and right thalamus by 4.1%, relative to controls. Individual volumetric analysis 
revealed abnormal volume of the left hippocampus in 9 (11%) patients, the right A
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hippocampus in 4 (4.9%) patients, the left thalamus in 14 (17.1%) patients, and the right 
thalamus in 7 (8.5%) patients. 
MRI correlations with clinical variables
There were no associations between volumes and seizure outcome at 6 or 12 months, 
EEG finding, loss of awareness during seizures, history of FBTCS, age at first seizure, 
years between first seizure and diagnosis or age at diagnosis. Table 3 presents the 
descriptive and statistical comparisons between outcome groups at 12 months. There 
were also no clinically significant differences between the individual patients who had 
significant loss of hippocampal and thalamic volume and those who did not. 
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Discussion
In the present study we sought to establish whether structures that are known to show 
atrophy in focal epilepsy also show evidence of volume loss at the time of diagnosis of 
epilepsy. We report significant volume loss of the thalamus and hippocampus in adults 
with NDfE. Additionally, we aimed to explore whether clinical variables were associated 
with volume changes. Atrophy of subcortical structures was not related to seizure 
outcome at either 6 or 12 months or any other clinical characteristic of epilepsy. 
Biological and clinical implications 
Of the limited number of quantitative MRI studies that exist in NDfE, the focus has been 
on the hippocampus. Our results are in support of those studies that reported 
hippocampal atrophy at diagnosis [11, 12, 22] and are in contrast to those that did not 
report atrophy [13]. Patients with chronic epilepsy have shown a 13 to 16% reduction in 
hippocampal volume compared to controls [22]; we identified a 6.5 to 6.9% decrease in 
hippocampal volume which may indicate hippocampal atrophy is present at time of 
diagnosis and may worsen with the progression of epilepsy. Although only left 
hippocampal volume reduction was significant after FDR correction, mean right 
hippocampal volume was similarly reduced in patients. This may suggest that both 
hippocampi are equally impacted at diagnosis and clearer insights would be achieved if 
the epileptogenic zone could be lateralised in newly diagnosed patients. The present 
study also sought to determine whether extrahippocampal subcortical atrophy was 
present at diagnosis. To our knowledge, the present study is the first to identify thalamic 
atrophy in adults with a new diagnosis of focal epilepsy. A previous study in a small 
sample of patients with NDfE did not report thalamic atrophy [13]. Thalamic atrophy has 
been reported to be almost as common as hippocampal atrophy in a meta-analysis of 
voxel-based morphometry studies of refractory TLE [23],  and is observed in a range of 
longstanding focal and generalised epilepsy disorders [2, 24]. Thalamic volume loss has 
also been reported in children with NDfE [25] and patients with new-onset GGE [15]. 
Consistent with our findings, volume loss of the thalamus in both hemispheres is 
frequently reported in patients with chronic focal epilepsy [2, 24, 26-28]. Taken together, 
our results suggest that thalamohippocampal atrophy is likely established prior to the A
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onset of habitual epilepsy; further hippocampal and thalamic damage may occur as the 
disorder becomes longstanding, particularly in refractory cases [29-31].  
There are very few existing studies that have attempted to predict pharmacoresistance 
from the point of diagnosis of focal epilepsy using advanced imaging in a way that 
resembles work predicting surgical outcome in focal epilepsy [27, 32]. This is an unmet 
need in the early stages of the disorder [4, 5, 33]. Having a reliable imaging biomarker of 
the health issues patients will experience (e.g. uncontrolled seizures, memory 
impairment) from diagnosis will provide clinicians and patients with realistic expectations 
and could serve to assist the patient management pathway (e.g. earlier use of adjunctive 
/ alternative therapies in patients likely to be pharmacoresistant) [33]. In the present study 
we have reported that gross neuroanatomical volume of subcortical structures are not 
related to seizure control at 6 or 12 months after diagnosis. It is likely that imaging 
markers of pharmacoresistance, if found, will be microstructural, functional, or metabolic. 
Interestingly, in patients with longstanding focal epilepsy, MR spectroscopy hippocampal 
N-Acetylaspartate/Creatine measurements have been related to seizure control [34].
Approximately 50% of patients with NDfE exhibit impairment in at least one cognitive 
domain [10]. Drug naïve patients with NDfE show significant impairments in memory, 
sustained attention, executive functioning, mental flexibility and psychomotor speed 
relative to healthy volunteers [35-40]. Cognitive deficits are therefore not necessarily a 
result of the chronicity of the disorder and may be at least partly driven by the 
pathological processes that lead to the generation of spontaneous seizures. Although we 
did not assess cognition in the current study, atrophy of subcortical structures may be 
related to cognitive impairment in patients with NDfE. 
Methodological issues
Following diagnostic MRI most patients with NDfE will not undergo further investigation, 
which is usually undertaken in those with a refractory course, for who more precise 
localisation of the seizure focus is more likely as more seizures are witnessed and 
following increasingly detailed imaging, EEG and neuropsychological evaluation. Our A
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sample of patients with NDfE is therefore likely to be clinically heterogenous in terms of 
seizure foci, despite commonalities in a new diagnosis of focal epilepsy of unknown 
cause and non-lesional MRI. It is difficult, most often impossible, to discern the 
epileptogenic focus in patients with a new diagnosis of focal epilepsy; diagnosis here is 
based on an epileptologist’s expertise in ascribing a likely diagnosis based on very few – 
sometimes singular – past events described by the patient and / or their family soon after 
the seizure(s). Inter-ictal EEGs are most frequently (76.5% of our sample) unrevealing 
and provide little diagnostic or localising information; the majority of patients with new 
onset seizures do not show inter-ictal epileptiform activity on clinical EEG [41-43]. As 
such, our imaging findings are ‘collapsed’ across patients with likely newly diagnosed 
non-lesional temporal and frontal lobe epilepsy, which constitutes the vast majority of 
focal epilepsies. This is an inherent shortcoming of our pragmatic approach, but this is 
necessary in imaging studies of NDfE [13, 44]. The epileptogenic focus could be 
determined by long-term follow up of newly diagnosed patients who later become 
refractory, experience many more seizures and be evaluated using a variety of 
investigative tools. However, most patients will not experience further seizures after 
starting AED treatment [7]; long term follow up is difficult in these patients. Furthermore, 
as per the exclusion criteria for this study, all patients did not have relevant histories that 
could be used to predict brain atrophy or pharmacoresistance. Future studies may relax 
exclusion criteria to identify predictors of pharmacoresistance in a more heterogeneous 
sample. We suggest that what is lost through the inclusion of a highly phenotyped group 
of patients is gained through a pragmatic approach to studying all non-lesional patients 
with a new diagnosis of focal epilepsy. 
The standard MRI protocol for patients with a new presentation of seizures at our 
institution does not include 3D volume scans that would be amenable to automated 
segmentation techniques. It was necessary for us to apply manual volumetric analysis 
due to the 3 mm slice thickness of the coronal 2D T1-weighted FLAIR MRI scans. 
Despite this being a time-inefficient way of obtaining morphometric data, there were 
distinct advantages to our approach. Firstly, manual measurement of brain regions is 
considered gold standard and stereology provides a mathematically unbiased and 
validated approach to estimate brain compartment volume [17, 21]. Secondly, despite the A
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non-isotropic voxel size, the high in-plane resolution and contrast of the scans provided 
excellent grey-white matter differentiation, even in regions where the grey matter and 
white matter borders are difficult to establish (e.g. the thalamus). Ultimately, gross brain 
volumetry appears not to be a biomarker of pharmacoresistance in patients with NDfE; 
more advanced imaging methods that permit analysis of brain connectivity and 
microscopic brain architecture in prospectively recruited newly diagnosed cohorts may 
identify such prognostic markers [33]. 
Conclusions 
Many specialist institutions and research centres do not see patients with epilepsy until it 
is well established, which may contribute to the lack of imaging studies of NDfE. In the 
present imaging study, we have studied a comparatively large number of patients with 
NDfE and report that atrophy of the hippocampi and thalami – ordinarily reported to be 
atrophic in longstanding and refractory focal epilepsy – is established at the time of 
diagnosis. It remains uncertain as to whether this atrophy is congenital, a consequence of 
epileptogenic processes or a combination of both.
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FIGURE LEGEND
Figure 1. T1-weighted fluid attenuated inversion recovery coronal sections through an 
exemplar patient showing point counting for stereology through the subcortical volumes 
of interest. For each structure, point counts are removed in the left hemisphere and 
coloured orange in the right hemisphere.  A, hippocampus; B, thalamus; C, caudate 
nucleus; D, putamen. Zoomed sections at the bottom of each panel show point counting 
in a rostral (top left) to caudal (bottom right) direction.
Figure 2. Scatterplots with minimum, 25th percentile, median, 75th percentile, and 
maximum normalised and corrected volume measurements of brain structures in seizure 
free patients, patients with persistent seizures, and healthy controls. Statistically 
significant between groups: *(P(FDRcorr) < 0.05), **(P(FDRcorr) < 0.01).
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Table 1. Demographic and clinical data. Mean age at diagnosis / MRI is presented with 
standard deviation. MRI, magnetic resonance imaging; FAS, focal aware seizures; FIAS, 
focal impaired awareness seizures; FBTCS, focal to bilateral tonic-clonic seizures; EEG, 
electroencephalography.
*Significantly different (X2 = 4.72, P = 0.03).
Clinical variable Patients Controls
n 82 40
Age at diagnosis / MRI 38.04 (10.8) 32.50 (8.9)
Sex 50 M / 32 F* 16 M / 24 F*
FAS 35 / 82 (42.7%) -
FIAS 47 / 82 (57.3%) -
FBTCS 72 / 81 (88.9%) -
Normal EEG 39 / 51 (76.5%) -
Abnormal EEG 12 / 51 (23.5%) -
Seizure free - 6 months 23 / 58 (39.7%) -
Seizure free - 12 months 24 / 48 (50%) -
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Table 2. Results of volumetric comparisons between patients and controls. Mean and 
standard deviation (SD) of subcortical and hemispheric volumes, expressed as 
percentage of whole brain volume and their residuals corrected for age and sex 
(%CorrAgeSex), and raw volume (cm3). For each structure the number (and percentage) 
of patients with volumes lower than the normal limits is indicated as abnormal (n, %).
Patients Controls
Structure Mean SD Abnormal 
(n, %)
Mean SD Abnormal 
(n, %)
U, P(FDRcorr)
Left hippocampus 
(%CorrAgeSex)
(cm3)
0.190
2.075
0.033
0.427
9, 11
19, 23.2
0.204
2.270
0.025
0.233
1, 2.5
0
U = 1232, P = 0.04
-
Right hippocampus
(%CorrAgeSex)
(cm3)
0.188
2.058
0.034
0.450
4, 4.9
10, 12.2
0.201
2.221
0.031
0.292
0
1, 2.5
U = 1311, P = 0.09
-
Left thalamus
(%CorrAgeSex)
(cm3)
0.642
7.021
0.068
0.915
14, 17.1
6, 7.3
0.686
7.609
0.055
0.934
1, 2.5
0
U = 1002, P = 0.002
-
Right thalamus
(%CorrAgeSex)
(cm3)
0.638
6.986
0.069
0.938
7, 8.5
6, 7.3
0.665
7.362
0.062
0.934
1, 2.5
0
U = 1228, P = 0.04
-
Left caudate 
(%CorrAgeSex)
(cm3)
0.371
4.054
0.054
0.634
5, 6.1
3, 3.7
0.368
4.063
0.040
0.487
1, 2.5
0
U = 1621, P = 0.46
-
Right caudate 
(%CorrAgeSex)
(cm3)
0.363
3.963
0.050
0.579
0
2, 2.4
0.355
3.932
0.044
0.509
1, 2.5
0
U = 1513, P = 0.39
-
Left putamen
(%CorrAgeSex)
(cm3)
0.467
5.091
0.051
0.493
3, 3.7
1, 1.2
0.464
5.111
0.043
0.474
0
0
U = 1623, P = 0.46
-
Right putamen
(%CorrAgeSex)
(cm3)
0.473
5.164
0.053
0.539
2, 2.4
0
0.469
5.176
0.044
0.551
0
1, 2.5
U = 1545, P = 0.39
-
Left hemisphere
(%CorrAgeSex)
(cm3)
49.98
550.3
0.66
56.7
5, 6.1
1, 1.2
49.95
549.5
0.50
52.5
0
0
U = 1550, P = 0.39
-
Right hemisphere
(%CorrAgeSex) 50.02 0.66 4, 4.9 50.05 0.50 0 U = 1550, P = 0.39A
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(cm3) 550.2 56.5 1, 1.2 551.4 51.3 0 -
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Table 3. Results of clinical and volumetric comparisons between seizure free patients 
and patients with persistent seizures at 12 months. FAS, focal aware seizures; FIAS, 
focal impaired awareness seizures; FBTCS, focal to bilateral tonic-clonic seizures; EEG, 
electroencephalography. †FBTCS data not available for one patient with persistent 
seizures. ‡EEG data not available for 11 (45.8%) seizure free patients and 10 (41.7%) 
patients with persistent seizures.
Structure Seizure free Persistent seizures X2, U, P(FDRcorr)
n (%) 24 (50) 24 (50) -
Male / female 14 (58.3) 10 (41.7) 14 (58.3) 10 (41.7) X2 = 0, P = 1.0
FAS / FIAS 11 (45.8) 13 (54.2) 7 (29.2) 17 (70.8) X2 = 1.42, P = 0.49
FTBS / no FTBS† 22 (91.7) 2 (8.3) 18 (75) 5 (20.8) X2 = 1.67, P = 0.49
Normal / abnormal EEG‡ 11 (45.8) 2 (8.3) 7 (29.2) 7 (29.2) X2 = 3.64, P = 0.41
Mean / SD
Age 39.71 12.22 37.00 10.25 U = 251, P = 0.45
Age of onset 32.21 12.33 29.33 11.01 U = 250, P = 0.45
Left hippocampus
(%CorrAgeSex)
(cm3)
0.193
2.101
0.032
0.369
0.175
1.926
0.035
0.507
U = 185, P = 0.34
-
Right hippocampus
(%CorrAgeSex)
(cm3)
0.189
2.070
0.028
0.336
0.172
1.892
0.041
0.520
U = 201, P = 0.37
-
Left thalamus
(%CorrAgeSex)
(cm3)
0.651
7.156
0.071
0.906
0.653
7.157
0.068
0.917
U = 280, P = 0.98
-
Right thalamus
(%CorrAgeSex)
(cm3)
0.654
7.209
0.064
0.923
0.646
7.084
0.051
0.792
U = 257, P = 0.98
-
Left caudate 
(%CorrAgeSex)
(cm3)
0.367
4.038
0.053
0.647
0.365
3.982
0.058
0.577
U = 288, P = 1.0
-
Right caudate 
(%CorrAgeSex)
(cm3)
0.355
3.894
0.052
0.614
0.363
3.963
0.051
0.503
U = 255, P = 0.98
-
Left putamenA
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(%CorrAgeSex)
(cm3)
0.468
5.134
0.045
0.367
0.462
5.059
0.055
0.618
U = 276, P = 0.98
-
Right putamen
(%CorrAgeSex)
(cm3)
0.469
5.150
0.047
0.528
0.461
5.042
0.054
0.571
U = 271, P = 0.98
-
Left hemisphere
(%CorrAgeSex)
(cm3)
50.00
553.7
0.63
56.2
49.94
549.7
0.54
56.7
U = 264, P = 0.98
-
Right hemisphere
(%CorrAgeSex)
(cm3)
50.00
553.1
0.63
55.4
50.06
550.8
0.54
56.6
U = 264, P = 0.98
-
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